Clinical trials: Behavioural Disorder
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
A three-arm, randomized, double-blind, placebo-controlled, Phase 4, multicenter study to compare the efficacy and safety of atomoxetine versus placebo in children and adolescents aged 6 through 17 years with…
- Trial name
- NCT00406354
- Testing
- Atomoxetine
- Where
- 6 sites in Germany
- Volunteers
- 181 people
- Sponsor
- Eli Lilly and Company
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention Deficit/Hyperactivity Disorder (ADHD)
To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07098585
- Testing
- Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Attention Deficit Hyperactivity Disorder
A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD
This 6-week study is to determine if the study drug, Methylphenidate Hydrochloride (HCl) Extended-Release Chewable Tablets (ERCT), is safe, tolerable and effective when compared to a sugar pill or placebo in children 4 to 5 years…
- Trial name
- NCT03536390
- Testing
- Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
- Sponsor
- Pfizer
Attention Deficit-Hyperactivity Disorder
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder
The main objective of the study is to demonstrate the non-inferiority of the personalized Neurofeedback Training device versus Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity…
- Trial name
- Newrofeed (NCT02778360)
- Testing
- Neurofeedback NFT, Methylphenidate MPH
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 179 people
- Sponsor
- Mensia Technologies SA
Attention Deficit Hyperactivity Disorder (ADHD)
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
- Trial name
- NCT06931080
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 630 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Disorder With Hyperactivity
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
- Trial name
- NCT00466791
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Noven Therapeutics
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder
A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD
The purpose of this study is to explore the preliminary safety and effectiveness of the digital therapeutic device 'NDTx-02' in supporting improvements of executive function in children and adolescents diagnosed with…
- Trial name
- NCT07242625
- Testing
- NDTx-02 + TAU, TAU
- Where
- 3 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Neudive Inc.
Attention Deficit Hyperactivity Disorder
Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD
Investigation of efficacy and tolerability of extended-release MPD in adults with ADHD, compared with a placebo, and to acquire knowledge through long-term observation of adults
- Trial name
- EMMA (NCT00619840)
- Testing
- methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
REM Sleep Behavior Disorder
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
This study is to investigate the safety and efficacy of PXS-4728A as an intervention therapy in participants with iRBD. This study will be conducted in participants aged 50 to 80 years of age and will investigate a single dose…
- Trial name
- NCT05904717
- Testing
- PXS-4728 (A)
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Syntara
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
- Trial name
- NCT04897074
- Testing
- AKL-T01
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Akili Interactive Labs, Inc.
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder (ADHD)
Effects of Probiotics on the Gut-brain Axis in Children
The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.
- Trial name
- NCT07459699
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Probi AB
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Mental Disorders
Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD
- Trial name
- yuyu (NCT01201187)
- Testing
- YY-162
- Where
- 3 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Yuyu Pharma, Inc.
Attention Deficit Disorder With Hyperactivity
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with…
- Trial name
- NCT04132557
- Testing
- Methylphenidate, Lisdexamfetamine, Atomoxetine
- Where
- United States
- Volunteers
- 430,000 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Fragile X Syndrome, Behavior
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS.
- Conditions
- Fragile X Syndrome, Behavior, Cognitive Dysfunction
- Trial name
- NCT05832255
- Testing
- Psilocybin, 1.5 mg
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Nova Mentis Life Science Corp
ADHD
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
- Trial name
- NCT00367835
- Testing
- SPD503 (Guanfacine hydrochloride)
- Where
- 34 sites in United States
- Volunteers
- 217 people
- Sponsor
- Shire